Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone agonist Buserelin.
Uterine arterial blood FVWs were studied by doppler ultrasound in eight patients with large uterine fibroids who were treated with the GnRH agonist Buserelin intranasally for 4 months. At the end of treatment, reductions in the uterine and discrete fibroid volumes were associated with significant increases in the mean RI values for the uterine (P less than 0.01) and fibroid (P less than 0.001) vasculature, thus indicating reduction in blood flow.
Matta
W H
WH
Academic Department of Obstetrics and Gynaecology, Royal Free Hospital School of Medicine, London, United Kingdom.
Stabile
I
I
Shaw
R W
RW
Campbell
S
S
D000328:Adult; D002064:Buserelin / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000098:blood supply* / Q000188:drug therapy; D012039:Regional Blood Flow / Q000187:drug effects; D012212:Rheology; D013997:Time Factors; D014594:Uterine Neoplasms / Q000098:blood supply* / Q000188:drug therapy; D014599:Uterus / Q000098:blood supply* / Q000187:drug effects
D002064:Buserelin